E
ENYO Pharma
Clinical stage biotech with an innovative approach inspired by viruses
About ENYO Pharma
ENYO Pharma is a biotechnology startup based in Brussels, Belgium, focused on developing innovative therapies for viral infections and liver diseases. The company leverages its proprietary discovery engine to identify and develop new drug candidates. ENYO Pharma's primary areas of research include chronic hepatitis B, non-alcoholic steatohepatitis (NASH), and COVID-19, among other viral threats.
Read full description
The company serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and research institutions. ENYO Pharma operates in the biopharmaceutical market, which involves the development and commercialization of drugs derived from biological sources.
ENYO Pharma's business model revolves around the research and development (R&D) of novel therapeutics. The company advances its drug candidates through various stages of clinical trials, aiming to demonstrate their safety and efficacy. Once a drug candidate shows promise, ENYO Pharma can either partner with larger pharmaceutical companies for further development and commercialization or bring the product to market independently.
The company generates revenue through multiple streams. These include licensing agreements, where other companies pay for the rights to develop and market ENYO Pharma's drug candidates. Additionally, ENYO Pharma may receive milestone payments as its drug candidates progress through clinical trials and regulatory approvals. The company also benefits from funding and grants, such as those from the European Union, to support its research initiatives.
ENYO Pharma's executive team comprises experienced leaders from the pharmaceutical industry and scientific experts in biology and drug development. This combination of expertise is crucial for driving the company's innovative approach and advancing its pipeline of drug candidates.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Lyon, France
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 84.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Missionfrenchtech, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Woman Founder, Horizon Europe, participations bpifrance
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jun 2025 | $6.6M | $220M | Vesalius Biocapital Partners | ↗ |
| SERIES COther financing | Jan 2024 | $43M | $220M | OrbiMed · InnoBio · Bpifrance · Morningside | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for ENYO Pharma is 4.1K monthly website visits, up 78.3% over the last three months. ENYO Pharma's team grew 10.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A7 investors entered at this stage
Sofinnova Partners
OrbiMed- INInnoBio
Bpifrance
Inserm Transfert Initiative
Andera Partners
5Y Capital
Series B and later2 investors entered at this stage
Morningside
Vesalius Biocapital Partners
Other known investors6 additional known investors
CNRS Innovation
ENS Lyon
French National Centre for Scientific Research - CNRS
INSERM
University of Lyon
University of Lyon - Claude Bernard Lyon 1
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ENYO Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ENYO Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.